In serum, increased sialylation at the overall level of the TF antigen-specific antibody is common in cancer, while in patients with breast cancer, the sialylation level of this antibody has been found to be reduced, and its sensitivity is increased, which shows its potential use as an antibody biomarkers in early breast cancer screening (Kurtenkov et al., 2018). Here, TF is linked to breast cancer.